The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
The effect of switching to Maraviroc + Darunavir/Ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis. Findings from a randomized study / Rossetti, B., Gagliardini, R., Sterrantino, G., Colangeli, V., Latini, A., Colafigli, M., Vignale, F., Rusconi, S., Di Biagio, A., Orofino, G., Mezzaroma, I., Vullo, V., Francisci, D., Mastroianni, C., Trezzi, M., Canovari, B., Lamonica, S., Ciccullo, A., Borghetti, A., D'Arminio Monforte, A., et al.. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - 81:1(2019), pp. e17-e21. [10.1097/QAI.0000000000001986]
The effect of switching to Maraviroc + Darunavir/Ritonavir dual therapy in virologically suppressed patients on the progression of liver fibrosis. Findings from a randomized study
Mezzaroma I.;Vullo V.;Mastroianni C.;
2019
Abstract
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.| File | Dimensione | Formato | |
|---|---|---|---|
|
Rossetti_effect_2019.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
156.9 kB
Formato
Adobe PDF
|
156.9 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
